ProPhase Labs, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
ProPhase Labs, Inc. (PRPH) reported Adjustments to Additional Paid in Capital, Warrant Issued of $1.26 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-06-01
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $1.26M.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $0.00.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-09-30 was $0.00.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $1.26M.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $398.00K.
- ProPhase Labs, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2015 was $14.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.26M derived: sum of 2 quarters · filed 2026-06-01 | $1.26M 10-K · filed 2026-06-01 | |
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-19 | $1.26M 10-Q · filed 2025-11-19 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $0.00 derived: sum of 3 quarters · filed 2025-04-01 | $398.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $398.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $398.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $398.00K 10-Q · filed 2024-05-10 | |||
| 2017-06-30 | $30.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | $43.00K 10-Q/A · filed 2018-08-20 | ||
| 2017-03-31 | $13.00K 10-Q/A · filed 2018-08-20 | |||
| 2015-12-31 | $14.00K 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |